Piper Sandler Raises Replimune Group (NASDAQ:REPL) Price Target to $14.00

Replimune Group (NASDAQ:REPL) had its price target hoisted by stock analysts at Piper Sandler from $13.00 to $14.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price suggests a potential upside of 80.65% from the company’s previous close.

Several other brokerages also recently commented on REPL. HC Wainwright upgraded shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Monday, October 27th. Wedbush raised their price target on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $3.00 to $13.00 in a research report on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. raised Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a report on Monday, October 20th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

Replimune Group Stock Up 11.8%

REPL stock opened at $7.75 on Thursday. The business’s 50-day moving average price is $8.77 and its 200-day moving average price is $7.19. The stock has a market cap of $639.92 million, a P/E ratio of -2.25 and a beta of 0.73. The company has a quick ratio of 6.31, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group has a twelve month low of $2.68 and a twelve month high of $14.80.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.08. On average, equities research analysts forecast that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling

In related news, insider Christopher Sarchi sold 5,208 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the transaction, the insider owned 123,088 shares in the company, valued at $1,120,100.80. The trade was a 4.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kapil Dhingra sold 3,169 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $10.40, for a total value of $32,957.60. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,625 shares of company stock valued at $257,607 over the last three months. 5.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently modified their holdings of the company. Saturn V Capital Management LP acquired a new position in shares of Replimune Group during the second quarter worth approximately $1,198,000. Squarepoint Ops LLC raised its stake in Replimune Group by 394.0% during the 2nd quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock valued at $631,000 after acquiring an additional 54,178 shares in the last quarter. Nan Fung Trinity HK Ltd. acquired a new position in Replimune Group during the 2nd quarter worth $4,325,000. Los Angeles Capital Management LLC bought a new position in shares of Replimune Group in the second quarter worth $403,000. Finally, TD Asset Management Inc grew its stake in shares of Replimune Group by 18.7% in the second quarter. TD Asset Management Inc now owns 327,452 shares of the company’s stock worth $3,042,000 after purchasing an additional 51,600 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.